← Back to patent-cliff list
NT-219
Tier C — Watch / tradeNT-219
TyrNovo Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：STAT3, INSR
Indications (approved)：Head and neck cancer, Head and neck squamous cell carcinoma, Colorectal cancer, Solid tumour
Regional status
US
Phase II
2020-09-03
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NT-219?
Approved indications include: Head and neck cancer, Head and neck squamous cell carcinoma, Colorectal cancer, Solid tumour.
When does the NT-219 patent expire?
No public expiry year is available for NT-219 yet; this page updates once verified.
How do I get a quote for NT-219 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06